Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, ...

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") , a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today ...

More than 80 international and regional healthcare experts have convened at the Pfizer MERA Maternal Immunization Summit: ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...

In exchange, 3SBio will receive $1.25bn upfront from Pfizer and will be eligible for certain development, regulatory and ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

CRISPR-edited iPSCs uncover early mitochondrial defects shared across ALS mutations, revealing pathways that could guide future treatments.

Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...